Free Trial

VolitionRx Q4 2022 Earnings Report

VolitionRx logo
$0.68 +0.09 (+16.33%)
(As of 12/20/2024 05:31 PM ET)

VolitionRx EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

VolitionRx Revenue Results

Actual Revenue
$0.12 million
Expected Revenue
$0.06 million
Beat/Miss
Beat by +$60.00 thousand
YoY Revenue Growth
N/A

VolitionRx Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

VolitionRx Earnings Headlines

VolitionRx’s Nu.Q cancer test shows efficacy in lung cancer detection
This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Q3 2024 VolitionRX Ltd Earnings Call Transcript
VolitionRx files $100M mixed securities shelf
See More VolitionRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email.

About VolitionRx

VolitionRx (NYSEAMERICAN:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

View VolitionRx Profile

More Earnings Resources from MarketBeat

Upcoming Earnings